Since diabetic hyperglycaemia causes hyperosmolarity, we investigated the contribution of hyperosmolarity in the proinflammatory endothelial effects of hyperglycemia, and sought to unravel the mechanisms involved. Human aortic endothelial cells (HAEC) were incubated for short-term (1-3 days) or long-term (1-2 weeks) exposures to 5.5 mmollL glucose (normoglycemia, basal), high glucose (25 and 45 mmollL, HG), or a hyperosmolar control (mannitol 25 and 45 mmollL, HM), in the presence or absence of the aquaporin-l (AQP1) inihibitor dimethylsulfoxide (DMSO), the Na+/H+ exchanger 1 (NHE-l) inihibitor cariporide (CA), the protein kinase C (PKC) inihibitor calphostin C or the PKCp isoform inhibitor LY379196 (LY). Both short-and long-term exposures to HG and HM decreased the expression of the active, phosphorylated form of endothelial nitric oxide synthase (Ser1146-eNOS) and, in parallel, increased vascular cell adhesion molecule(VCAM)-1 protein at immunoblotting. After 24 h incubation with HG/HM, we observed a significant similar and concentration-dependent enhancement of AQPl expression. DMSO and CA inhibited hyperosmolarity-induced VCAM-l expressions, while increasing nitrite levels and Ser1146-eNOS expression. Gene silencing by small interfering RNA reduced the expression of AQP1, and suppressed HG-and HM-stimulated VCAM-l expression. Calphostin C and LY blunted hyperosmolarity-induced VCAM-l expression, while increasing the expression of Ser1146-eNOS and nitrite production. Thus HG decreases eNOS activation and induces total VCAM-l expression in HAEC through a hyperosmolar mechanism. These effects are mediated by activation of the water channels AQPl and NHE-l, and a PKC~-mediated intracellular signaling pathway. Targeting osmosignaling pathways may represent a novel strategy to reduce vascular effects of hyperglycemia.
activation of early-response and heat-shock genes (10) . Aquaporins (AQPs) and sodium/hydrogen exchangers (NHEs) are membrane-associated proteins mainly involved in the transmembrane transport ofwater driven by osmotic gradients. NHE-I, one of 6 isoforms recognized, is ubiquitously distributed in the mammalian cardiovascular system ( 11), and is thought to playa critical role in vascular injury in diabetes (12) (13) . On the other hand, the expression of aquaporin subtype I (AQPl), which predominates in endothelial ( 14) and smooth muscle cells (15) , is induced by hyperosmotic agents, such as glucose, sucrose, sorbitol, urea and sodium chloride (16) . In skin keratinocytes, membrane AQP expression is increased in response to pathophysiological stresses, such as inflammation (17) and skin dryness in atopic eczema (18) .
We therefore studied hyperosmolarity-mediated changes of endothelial function, in terms of decreased nitric oxide production and increased YCAM-l expression, in endothelial cells exposed to high glucose, and postulated a link of such changes with abnormal water/ion movements mediated by the activities of water channels AQP I and NHE-I.
MATERIALS AND METHODS

Materials
D-glucose, mannitol (devoid of metabolic activities and used as a purely hyperosmolar control), the AQPI inihibitor dimetylsulfoxide (DMSO) (19) , the non-specific PKC inhibitor calphostin C and the PKC activator phorbol 12-myristate 13-acetate (PMA) were purchased from Sigma (Sigma-Aldrich, St. Louis, MO). The selective inhibitor of PKC~, LY379196 was provided by Eli Lilly (Indianapolis, IN) . The selective inhibitor of NHE-I, cariporide (20) was kindly provided by Sanofi-Aventis (Frankfurt, Germany).
Cell cultures
Subconfluent human aortic endothelial cells (HAEC, purchased from Clonetics, Baltimore, MD) at passage 3 were starved in Endothelial Growth Medium (Clonetics) containing 2% fetal calf serum (FCS) for 24 h, then incubated with control glucose concentration (5.5 mmol/ L, control), high glucose (HG, 25 or 45 mmol/L), or high mannitol (HM, 25 or 45 mmol/L), for short-term (\ -3 days) experiments, in the presence or absence of 1% DMSO or I umol/L cariporide, or 300 nmol/L LY379196 or 500 nmol/L calphostin C. For long-term incubations (1-2 weeks), subconfluent HAEC at passage 3 were used in non-starved culture conditions. Control experiments were performed using human umbilical vein endothelial cells (HUVEC) (21) . CelI viability after treatments was assessed by celI morphology at phase-contrast microscopy, Trypan blue exclusion, total protein content and the surface expression of E I/ I (21) .
Flow cytometry analysis
Assays of VCAM-I expression were carried out by flow cytometry, using fluorescein (FITC)-conjugated mouse anti-VCAM-I antibody or an IgG isotype control antibody (Santa Cruz, CA). HAEC (I x I0 6 ) were fixed with cold methanol for 15 min and then permeabilized in PBS/ 2% FCS/O.I% Triton for 10 min. Cells were incubated for 60 min at 4°C directly with the FITC-conjugated mouse anti-VCAM-I antibody or the corresponding control antibody.
Immunoblotting
Total proteins were isolated In an ice-cold Radiolmmuno Precipitation Assay (RIPA) buffer. Proteins were separated under reducing conditions and electroblotted onto polyvinylidene fluoride membranes (Immobilon-P; Millipore, Bedford, MA). After blocking, the membranes were incubated overnight at 4°C with the following primary antibodies: (I) VCAM-I (R&D Systems, Minneapolis, MN); (2) ICAM-I (Santa Cruz); (3) Serl146-phosphorylated endothelial nitric oxide synthase (eNOS, NOS III) (CelI Signaling Technology, Danvers, MA); (4) AQPI (Santa Cruz, CA); (5) NHE-I (Santa Cruz). Equal loading/equal protein transfers were verified by stripping and reprobing each blot with an antibeta-actin antibody (Sigma).
Nitrite assays
Nitrite, a stable end-product of nitric oxide, was measured using the Griess reagent (I % sulphanilic acid and 0.1% N-[ I-naphtyl] ethylenediamine-HCI in 5% phosphoric acid, Sigma), according to the manufacturer's protocol. Nitrite concentrations were calculated from a linear standard curve constructed with known concentrations of sodium nitrite (0-14 umol/L),
Transfection ofAQPI siRNA
SmalI interfering RNA (siRNA) oligonucleotides to AQPI and scrambled control siRNA were obtained from Ambion. HAEC (2 x 10 5 /well) were plated on 6 welI-plates in low-serum medium without antibiotics (OptiMem, Invitrogen) and incubated with 6~L of siRNA transfection reagent mixed with siRNA (60~M) up to a total volume of 800~L transfection medium. After 24 h, fresh medium was added with or without C total VCAM-l M2 cau 10 1 ,02 10 glucose or mannitol (25 and 45 mMoI/L) and incubated for an additional 16 h, then cells were harvested by using EDTA/PBS without trypsin, and proteins were extracted for YCAM-I, AQPI and 13-actin Western analysis. Transfection efficiency was checked by using 2 x 10 5 cells seeded in 6-well plate (at 80% confluence) and delivering Cy5-conjugated-AQP I siRNA. means of 2:3 groups were performed by analysis of variance (ANOYA), and the existence of individual differences, in case of significant F-values at ANOYA, tested by Scheffe's multiple contrasts.
RESULTS
Statistical Analysis
Two-group comparisons were performed by the Student's t-test for unpaired values. Comparisons of
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Exposure to either high glucose or high mannitol 
. Western analysis of the effect ofhigh glucose and high mannitol on ICAM-I and the effect ofAQPI and NHE-1 inhibitors on high glucose-and high mannitol-induced VCAM-I expression in endothelial cells. A) Upper panel:
Immunoblotting with an antibody against ICAM-I ofcellular proteins extractedfrom subconfluent serum-starved HAEC for 24 h and then incubated with stimuli (glucose or mannitol) for 3 days. 10 ng/mL LPS has been used as positive control for the expression ofICAM-I . increased protein expression of YCAM-I after both short-term (1-3 days) and long-term (1-2 weeks) incubations at Western analysis ( Fig. I A) . Equal loading/equal protein transfers were verified by protein band detection with the anti-Bvactin antibody (Fig. I B) . Such effects were more pronounced after 3 days of incubation. Flow cytometry confirmed these results (Fig. I C) . Similar results were obtained for ICAM-I ( Fig. 2 A) .
BlockadeofAQPl andNHE-l prevents hypertonicityinduced VCAM-l expression
Because AQP I and NHE-I are important membrane proteins involved in mediating the intracellular effects ofhyper0 smolarity in endothelial cells (22) , we tested whether hyperosmolarity increased YCAM-I expression viaAQPI-and NHE-I-dependent mechanisms. The exposure of HAEC to a high-o smolarity medium by the addition of glucose and mannitol (from 25 mmol/L to 45 mmo llL, Fig.  3 , and higher, up to 200 mmollL, data not shown ), per se and in a concentration-dependent fashion increased NHE-I (Panels A and B) and AQPI expression (Panels C and D) at Western analysis. Treatment of HAEC with pharmacological (DMSO) and molecular (siRNA) inihibitors ofAQP I ( Fig. 2 B  and Fig. 4 ), as well as the NHE-I inhibitor cariporide (Fig. 2 C) partially reverted both high glucose-and high mannitol-induced total protein expression of YCAM-I after both I and 3 day-incubations. Cotreatment with 1% DMSO and I umol/L cariporide ( Fig. 2 D) totally reverted both high glucose-and high mannitol-induced total protein expression of YCAM-I. The effects ofNHE and AQPI inhibitors were specific , since none of the inhibitors had any effect on cell viability (data not shown). To ensure that the reversion of the stimulatory effect of hyperosmolarity on YCAM-I expression following incubation with AQPI inhibitor was effected through a spec ific inhibition ofAQP I and not due to non-specific activity of DMSO, siRNA technology for AQPI was utilized . Two different species of siRNA were used. As shown in Fig. 5 , AQPI siRNA resulted in a substantial -albeit incomplete -knockdown of AQPI protein expression. As a control for the specificity of the siRNA approach, we determined the expression ofAQP I after transfection with a scrambl ed sequence of siRNA serving as a sequence-unrelated control, which was essentially unchanged (Fig. 5 ). Proteins from AQP l-siRNAtransfected cells were probed for YCAM-I . YCAM-I expression in high glucose-and high mannitoltreated cells was suppressed after transfection with siRNA against AQPI , consistent with the findings with DMSO (Fig. 4) . These results suggest that high glucose (or high mannitol)-induced hypero smolarity Fig. 6 B) , significantly reverted both high glucoseand high mannitol-induced total protein expression of YCAM-1 after 3-day incubations. PMA (at 100 nmol/L), a non-selective PKC agonist used as positive control, mimicked the effect ofboth HG and HM (Fig. 1 C) . LY379196 blunted PMA-stimulated YCAM-1 expression ( Fig. 1 C) . These data indicate that PKC13 contributes to the stimulatory effect of hyperosmolarity on YCAM-I expression in HAEC. participates in YCAM-I expression through the activation of an "inflammatory" water channel (i.e., AQP1 and NHE-1)-mediated pathway, which might playa role in the mechanisms of diabetes-associated endothelial inflammation and atherosclerosis.
Role of PKC~on high glucose-and high mannitolinduced VCAM-I expression
Downstream of AQPI (23) and NHEs (24) , the activation of PKCs are well-characterized signaling pathways whereby extracellular hyperosmolarity exerts its cellular effects. We examined whether hyperosmolarity enhances YCAM-I expression through PKC-mediated intracellular signaling
High glucose and high mannitol cause inhibition of endogenous nitric oxide production in cultured endothelial cells
Nitric oxide (NO), either provided exogenously through NO donors or endogenously, is reported to suppress cytokine-induced expression of endothelial leukocyte adhesion molecules (21) . In an attempt to identify differences in the endogenous production of NO, which might account for the observed modulation of YCAM-1 expression, we analyzed the activation of endothelial nitric oxide synthase (eNOS) by immunoblotting with antibodies directed against the active form of eNOS (Serl146-eNOS) (25) . Both HG and HM decreased the phosphorylation of eNOS at Serl146 in HAEC, both after short-term (1-3 days) and long-term (1-2 weeks) incubations at Western analysis. Such effects were more pronounced after 3 days of incubation ( Fig.  7 A and B and Fig. 8 A) . Furthermore, both short-( 1-3 days) and long-term incubations (6-12 days) produced significant reductions in endotheliumdependent nitrite production, with this effect being maximal after 3 days incubation (Fig. 8 B) . One % DMSO ( Fig. 7 A) , as well as I umol/L cariporide ( Fig. 7 B) , reverted the inhibition of Ser-1146 eNOS expression. Furthermore, LY913136 completely reverted the inhibition of Ser-1146 eNOS expression ( Fig. 8 A) and NO production ( Fig. 8 B) .
Similar results in each of the above-reported experiments were obtained by using human umbilical vein endothelial cells (HUYEC) (data not shown).
DISCUSSION
We show here that osmotic stress, at levels produced by diabetic hyperglycemia, increases VCAM-l expression and decreases eNOS activity in cultured human endothelial cells. Culture conditions used in this study reflect glucose levels commonly encountered in patients with uncontrolled diabetes, and have been used in previous experiments in the same cellular system (2) . Our results demonstrate that the effects of HG on VCAM-l expression are largely dependent on the hyperosmolar component of hyperglycemia, since they are mimicked by the exposure of cells to the metabolically inactive monosaccharide mannitol. Although concentrations of glucose outside the range tested might exert more specific effects, therefore not ruling out completely the additional involvement of mechanisms different from hyperosmolarity (which however appear to be insignificant with glucose concentrations ::;25 mmol/ L), such findings expand and refine data previously reported related to glucose (4). The regulation by osmotic stress requires "osmosensing" structures, which can sense osmolarity changes, and "osmosignaling" pathways, which can transmit the signal towards effector regulatory sites. NHEs and AQPl are well-described osmosensing structures that might contribute to the hyperosmolarity-induced cellular responses in human endothelial cells (22) . Because the inhibition ofNHE-l andAQPl prevented the hyperosmolarityinduced enhancement ofVCAM-l expression and the parallel reduction observed in eNOS in our study, we can conclude that these osmosensing structures play a role in the glucose and hyperosmolarity-induced chain of events in endothelial cells leading to the measured effects. Although a role for NHEs (26) and AQPs (17) (18) in the regulation of inflammatory responses had been reported previously, our study is the first to demonstrate that isoforms 1 of NHEs and AQPs regulate hyperosmolarity-induced VCAM-l expression in human endothelial cells. Similarly, we also show here that the reduction in endothelialdependent nitrite production is also mediated through hyperosmolarity-elicited osmosensing structures (i.e., AQPl and NHE-l), and the osmosignaling PKCj3 intracellular pathway. Such involvements appear therefore similar to that discussed for the expression ofVCAM-l.
In conclusion, our study shows that concentrations of glucose attainable in conditions of hyperglycemia increase VCAM-I protein and decrease NO production in human endothelial cells through an AQP 1 and an NHE-I hyperosmolar mechanism. Such effects, together with mechanisms other than direct glucotoxicity, for example the induction of glucose-induced protein and lipid modifications -the advanced glycation endproducts (AGEs) (27) -, are prevalent in explaining endothelial activation observed after exposure of the vascular endothelium to high glucose in vivo. Correction of hyperosmolarity by targeting its osmosignaling pathway may thus represent a novel strategy to counteract the detrimental vascular consequences of diabetic hyperglycemia.
